Clinical utility of anti-interleukin 5 monoclonal therapy in asthma using a national, centralised, outcome-based system of drug access

INTRODUCTION: Interleukin 5 (IL-5) inhibitors are an important therapeutic advance in the management of severe, refractory, eosinophilic asthma. However, their utilisation should be targeted to maximise their benefits. This study used multisite, centralised, national data collected over 18 months to...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Leary, Caroline, Schultz, Christopher, Walsh, Cathal, Adams, Roisin, Casey, Deborah, Lane, Stephen, Harrison, Michael, Doyle, Shane, Costello, Richard W, King, Fionnuala, Murphy, Desmond M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Asthma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516070/
https://www.ncbi.nlm.nih.gov/pubmed/36167473
http://dx.doi.org/10.1136/bmjresp-2022-001341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516070/
https://www.ncbi.nlm.nih.gov/pubmed/36167473
http://dx.doi.org/10.1136/bmjresp-2022-001341

Ejemplares similares